Phase 3 Drug Trial for Advanced Breast Cancer by AstraZeneca Shows Good Results in First-line Treatment

Phase 3 Drug Trial for Advanced Breast Cancer by AstraZeneca Shows Good Results in First-line Treatment
AstraZeneca has revealed positive data from its FALCON Phase 3 clinical trial for metastatic breast cancer. More specicically, the trial evaluated Faslodex  (fulvestrant) versus Arimidex (anastrozole) as a treatment option for metastatic or locally-advanced breast cancer, in post-menopausal women who had not been previously treated with hormonal treatment for hormone-receptor-positive (HR+) breast cancer. Compared to Arimidex, Faslodex showed clinical superiority. The Phase 3 FALCON (Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer) trial met the study's primary goal of prolonged progression-free survival. Results from the clinical study demonstrated adverse side effects expected, and consistent with knowlege that already existed about the drugs. According to a press release, Sean Bohen, executive vice president of Global Medicines Development and chief medical officer at AstraZeneca, said: “The FALCON results bring us closer to offering more and earlier treatment options to postmenopausal women with HR+ locally-advanced or metastatic breast cancer; the potential to delay disease progression is important for these patients as there is currently no cure. Faslodex has over 10 years of clinical evidence and we are committed to exploring its potential along with the rest of our outstanding oncology portfolio.” Aromatase inhibitors like Arimidex are currently the first-line gold standard of care for postmenopausal women with a diagnosis of advanced HR+ breast cancer - which usually refers to metastatic breast cancer, or Stage 4 breast cancer, be
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.